SCHEMBL24542246

SCHEMBL24542246

COc1cc2ncc(-c3nc(N[C@@H]4CCCNC4)c(F)cc3F)n2nc1C1CC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NRAS P01111 10/20 0.56
▸ FLT3 P36888 10/20 0.56
▸ CDK7 P50613 4/20 0.41
▸ CCNH P51946 4/20 0.41
▸ MNAT1 P51948 2/20 0.41
▸ CHEK1 O14757 2/20 0.38
▸ CDK2 P24941 2/20 0.37
▸ MAPKAPK2 P49137 1/20 0.37
▸ IRAK1 P51617 3/20 0.37
▸ IRAK4 Q9NWZ3 3/20 0.37
▸ PDGFRB P09619 2/20 0.37
▸ LCK P06239 1/20 0.37
▸ RET P07949 1/20 0.37
▸ CHEK2 O96017 1/20 0.36
▸ ABL1 P00519 1/20 0.36
▸ PDGFRA P16234 1/20 0.36
▸ FLT4 P35916 1/20 0.36
▸ KDR P35968 1/20 0.36
▸ DDR1 Q08345 1/20 0.36
▸ NTRK3 Q16288 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27198198 1.00 NRAS (0.56) NRASFLT3CDK7CCNHMNAT1
SCHEMBL27330375 0.97 NRAS (0.55) NRASFLT3CDK7CCNHMNAT1
SCHEMBL31740008 0.97 NRAS (0.55) NRASFLT3CDK7CCNHMNAT1
SCHEMBL27327743 0.97 NRAS (0.55) NRASFLT3CDK7CCNHMNAT1
SCHEMBL27330153 0.97 NRAS (0.55) NRASFLT3CDK7CCNHMNAT1
SCHEMBL27330287 0.97 NRAS (0.54) NRASFLT3CDK7CCNHMNAT1
SCHEMBL27327588 0.97 NRAS (0.54) NRASFLT3CDK7CCNHMNAT1
SCHEMBL27331193 0.95 FLT3 (0.61) NRASFLT3CDK7CCNHMNAT1
SCHEMBL31740029 0.94 NRAS (0.53) NRASFLT3CDK7CCNHMNAT1
SCHEMBL27327569 0.94 NRAS (0.53) NRASFLT3CDK7CCNHMNAT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12534469-B2 Multi-cyclic IRAK and FLT3 inhibiting compounds and uses thereof CHILDREN'S HOSPITAL MEDICAL CENTER (US) 2026-01-27 — — US disclosed
US-20250368648-A1 MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF CHILDREN'S HOSPITAL MEDICAL CENTER (US) 2025-12-04 — — US disclosed
US-20240124468-A1 MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF CHILDREN'S HOSPITAL MEDICAL CENTER 2024-04-18 — — US disclosed
WO-2024030908-A1 MULTI-CYCLIC IRAK1 AND IRAK4 INHIBITING COMPOUNDS AND USES THEREOF CHILDREN'S HOSPITAL MEDICAL CENTER (US) 2024-02-08 — — WO disclosed
WO-2023245123-A2 MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF CHILDREN'S HOSPITAL MEDICAL CENTER (US) 2023-12-21 — — WO disclosed
WO-2022132936-A1 MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF CHILDREN'S HOSPITAL MEDICAL CENTER (US) 2022-06-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124468-A1 MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF FLT3, IRAK1, IRAK2 NRAS 372/4885FLT3 1/4885CDK7 589/4885
US-20250368648-A1 MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF FLT3, IRAK1, IRAK2 NRAS 371/4885FLT3 1/4885CDK7 591/4885
US-12534469-B2 Multi-cyclic IRAK and FLT3 inhibiting compounds and uses thereof FLT3, IRAK3, IRAK2 NRAS 277/4885FLT3 1/4885CDK7 382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback